MariMed Inc. (OTCMKTS:MRMD - Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 24,600 shares, a growth of 52.8% from the August 31st total of 16,100 shares. Based on an average daily volume of 5,181,900 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 5,181,900 shares, the short-interest ratio is presently 0.0 days.
MariMed Trading Up 6.5%
Shares of MRMD opened at $0.17 on Tuesday. The stock's fifty day simple moving average is $0.13 and its 200 day simple moving average is $0.10. MariMed has a twelve month low of $0.07 and a twelve month high of $0.23. The company has a current ratio of 1.12, a quick ratio of 0.36 and a debt-to-equity ratio of 1.25. The firm has a market capitalization of $64.78 million, a P/E ratio of -5.50 and a beta of 2.98.
Analyst Ratings Changes
Separately, Zacks Research raised MariMed from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Strong Buy".
Get Our Latest Analysis on MRMD
MariMed Company Profile
(
Get Free Report)
MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MariMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MariMed wasn't on the list.
While MariMed currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.